Research News
View articles by month and year
21–30 of 31 articles
-
Zometa Helps Keep Bones Strong During Hormonal Therapy
Zometa helps keep bones strong in pre-menopausal women getting hormonal therapy to treat hormone-receptor-positive, early-stage breast cancer.
-
Zometa May Reduce Recurrence Risk
New research suggests that Zometa, a bone-strengthening medicine, may help lower the risk of breast cancer coming back in premenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer who aren't being treated with chemotherapy.
-
High Estrogen Levels May Lead to Recurrence
Women diagnosed with early-stage breast cancer that came back (recurred) had higher blood estrogen levels than women diagnosed with early-stage breast cancer that didn't come back.
-
Arimidex More Effective Than Tamoxifen for Postmenopausal Women
Another year of results from the ATAC trial continues to show that Arimidex has more benefits than tamoxifen for post-menopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer.
-
Postmenopausal Women Benefit from Longer Hormonal Therapy
Taking Arimidex for 3 years after 5 years of tamoxifen reduced the risk of the cancer coming back in women diagnosed with hormone-receptor-positive breast cancer.
-
Chemotherapy and Aromatase Inhibitors Can Cause Bone Loss
A new study provides more evidence that bone loss is a significant risk for women who receive chemotherapy and/or an aromatase inhibitor to treat breast cancer.
-
Women Stop Taking Hormonal Therapy Too Soon Because of Side Effects
Side effects cause many women to stop taking hormonal therapy medicine earlier than prescribed a new study reports.
-
Hormonal Therapy Medicines Have Improved Survival
Hormone-receptor-positive breast cancer survival rates have increased faster than survival rates for hormone-receptor-negative breast cancer.
-
Aromatase Inhibitors Offer Better Survival Than Tamoxifen for Postmenopausal Women
Switching to an aromatase inhibitor after two to three years of tamoxifen offers improved survival compared to five years of tamoxifen for post-menopausal women with hormone-receptor-positive, early-stage breast cancer.
-
Too Many Women Stop Taking Tamoxifen Early
Many women stop taking adjuvant hormonal therapy medicine earlier than prescribed by their doctors.
21–30 of 31 articles
